MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Carboplatin

Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin

Clinical Cancer Research. 2011 Apr 15;17(8):2581-90. Epub 2011 Jan 24. [Link] Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A. Department of Oncology, Biostatistics Unit, Istituto Clinico Humanitas IRCCS, […]

Comments Off on Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin

Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent

Lung Cancer. 2009 May;64(2):211-8. Epub 2008 Nov 29. [Link] Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C, Stahel R. Cardarelli Hospital, Medical Oncology, Via Cardarelli 9, 80100 Naples, Italy. giacomo.carteni@ospedalecardarelli.it Abstract Aim: Peritoneal mesothelioma (PM) has rarely been studied. The Expanded Access Program (EAP) provided […]

Comments Off on Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent

Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study

Journal of Thoracic Oncology. 2008 Nov;3(11):1325-31. [Link] Hillerdal G, Sorensen JB, Sundström S, Riska H, Vikström A, Hjerpe A. Department of Lung Medicine and Allergology, Karolinska University Hospital, Solna, Stockholm, Sweden. gunnar.hillerdal@karolinska.se Abstract Background: Malignant pleural mesothelioma has a poor prognosis and there is limited effect of treatment. The Nordic Mesothelioma groups decided in the […]

Comments Off on Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study

Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: A realistic treatment option?

Lung Cancer. 2008 Oct 14. [Epub ahead of print] [Link] Li L, Razak AR, Hughes A. Department of Medical Oncology, Northern Centre for Cancer Treatment (NCCT), Westgate Road, Newcastle upon Tyne NE4 6BE, United Kingdom. Abstract Background: Malignant pleural mesothelioma is an aggressive cancer. Chemotherapy with cisplatin and pemetrexed can improve overall survival but has […]

Comments Off on Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: A realistic treatment option?

Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin

Journal of the Egyptian National Cancer Institute. 2007 Mar;19(1):61-70. [Link] Ryad AY, Mostafa E, Salem DA, Al-Adwy ER, Margerges M. The Departments of Radiation Oncology&Nuclear Medicine, Ain Shams University. Abstract Purpose: To evaluate the efficacy, safety, and clinical benefit of combined gemcitabine and carboplatin in patients with previously untreated malignant pleural mesothelioma (MPM). Patients and […]

Comments Off on Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

Therapeutics and Clinical Risk Management. 2008 Jun;4(3):579-85. [Link] Felip E, Rosell R. Vall d’Hebron University Hospital Barcelona, Spain. Abstract NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause of cancer mortality. The majority of NSCLC patients present with advanced, unresectable disease, which remains incurable. In advanced disease, chemotherapy with […]

Comments Off on Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program

Journal of Thoracic Oncology. 2008 Jul;3(7):756-63. [Link] Santoro A, O’Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C. Istituto Clinico Humanitas, Rozzano, Italy. armando.santoro@humanitas.it Abstract Introduction: Previously published results from a randomized phase III study of pemetrexed plus […]

Comments Off on Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials

British Journal of Cancer. 2008 Jun 10. [Epub ahead of print] [Link] Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, Cortinovis D, Conte GD, Ceribelli A, Bearz A, Salamina S, De Vincenzo F, Cappuzzo F, Marangolo M, Torri V, Santoro A. 1Department of Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Milano, Italy. […]

Comments Off on Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials

Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599

Clinical Lung Cancer. 2008 Mar;9(2):102-5. [Link] Somer RA, Sherman E, Langer CJ. Department of Medical Oncology, Cooper Medical Center, Cherry Hill, NJ, USA. Abstract Background: In a previous randomized phase II trial evaluating carboplatin and paclitaxel with or without bevacizumab in patients naive to chemotherapy with advanced non-small-cell lung cancer (NSCLC), median survival ranged from […]

Comments Off on Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599

Pericardial malignant mesothelioma: a latent complication of radiotherapy?

European Journal of Cardiothoracic Surgery. 2008 Feb 13 [Epub ahead of print] [Link] Small GR, Nicolson M, Buchan K, Broadhurst P. Department of Cardiology, University of Aberdeen, Aberdeen, Scotland AB25 2ZN, United Kingdom. Abstract Pericardial diseases can be difficult to differentiate from myocardial conditions. Diagnosis can be challenging and often requires the use of different […]

Comments Off on Pericardial malignant mesothelioma: a latent complication of radiotherapy?